Clarivate(US:CLVT)2025-07-30 13:00Financial Performance - Revenues for Q2 2025 were $621 million, a decrease of $29 million compared to Q2 2024[58] - Adjusted EBITDA for Q2 2025 was $262 million, with a margin of 42.1%[15, 58] - Adjusted Diluted EPS for Q2 2025 was $0.18, a decrease of $0.02 year-over-year[15, 58] - The company utilized free cash flow to repurchase 11.5 million shares in Q2 2025[13] - H1 2025 Free Cash Flow conversion was 32%[13] Business Segments and Growth - Organic ACV grew by 1.3%, up 10 bps sequentially[13] - The renewal rate was 93%, an increase of 1% year-over-year[13] - Academia & Government (A&G) segment experienced 2% organic ACV & subscription revenue growth in H1 2025[13] - Intellectual Property (IP) segment returned to organic revenue growth in patent annuities in H1 2025[13] - Life Sciences & Healthcare (LS&H) segment returned to organic ACV growth in H1 2025[14] Strategic Initiatives and Outlook - The company is pursuing a refined path forward based on insights from the initial evaluation process of strategic alternatives and expects to complete the review and share the outcome with year-end results[46] - The company reaffirms FY 2025 guidance, expecting revenues of approximately $2390 million and Adjusted EBITDA of approximately $980 million[80]